Coronary Artery Disease Risk in Familial Combined Hyperlipidemia and Familial Hypertriglyceridemia
Open Access
- 5 August 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (5) , 519-523
- https://doi.org/10.1161/01.cir.0000081777.17879.85
Abstract
Background— Conventional wisdom suggests that a diagnosis of familial combined hyperlipidemia (FCHL) carries a substantially greater risk of premature coronary artery disease (CAD) than a diagnosis of familial hypertriglyceridemia (FHTG). However, no population-based studies have critically addressed this issue. Methods and Results— FCHL and FHTG were diagnosed in 10.2% and 12.3% of 334 random control families and in 16.7% and 20.5% of 293 families with at least one case of premature CAD. The diagnosis of either FCHL or FHTG in an individual was associated with an odds ratio for CAD of 2.0 ( P =0.003 and 0.002, respectively). However, odds ratios for premature CAD associated with both lipid disorders decreased substantially and identically with further adjustment for hypertension, diabetes, and especially HDL cholesterol, triglycerides, or apolipoprotein B. Similar results were found for differences in carotid intima-medial thickness and ankle-brachial index. Metabolic syndrome was identified in 65% of FCHL and 71% of FHTG patients compared with 19% in controls without FCHL or FHTG and was associated with an odds ratio of 3.3 ( P Conclusions— FCHL and FHTG appear more alike than dissimilar. Further, the risk of CAD in FCHL and FHTG was strongly related to features of the metabolic syndrome. These findings suggest that the hypertriglyceridemia in FHTG is not benign and may warrant a change in epidemiological, genetic, and clinical approaches to these lipid disorders.Keywords
This publication has 20 references indexed in Scilit:
- Recognition of familial dyslipidemias in 5-year-old children using the lipid phenotypes of parents: The STRIP projectAtherosclerosis, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Co-segregation of elevated LDL with a novel mutation (D92K) of the LDL receptor in a kindred with multiple lipoprotein abnormalitiesJournal of Human Genetics, 2000
- Coexisting dysbetalipoproteinemia and familial hypercholesterolemia: Clinical and laboratory observationsAtherosclerosis, 2000
- Hypertension, dyslipidemia, and insulin resistance: links in a chain or spokes on a wheel?Current Opinion in Lipidology, 1996
- Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular geneticsPublished by Elsevier ,1993
- Genetics and molecular biology of familial combined hyperlipidemiaCurrent Opinion in Lipidology, 1993
- Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. A possible pathophysiologic explanation for familial combined hyperlipidemia.Journal of Clinical Investigation, 1991
- Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation.Journal of Clinical Investigation, 1990
- Very low density lipoprotein triglyceride metabolism in relatives of hypertriglyceridemic probands. Evidence for genetic control of triglyceride removal.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1988